Literature DB >> 24426730

Role of NF-κB as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients.

D K Sarkar1, Debarshi Jana2, P S Patil3, K S Chaudhari4, B K Chattopadhyay5, B R Chikkala6, S Mandal7, P Chowdhary5.   

Abstract

The nuclear factor κB (NF-κB) is a superfamily of transcription factors. It plays an important role in development & progression of cancer. This study was conducted in a tertiary care centre to investigate the significance of NF-κB as a prognostic marker in breast cancer and study its relation with established prognostic markers such as tumor grade, lymph node status, hormone receptor & HER-2/neu expression. We measured NF-κB expression of breast cancer tissue as a test sample & from fibroadenoma as a control. Measurement was done by Western Blot Technique using p65 protein of NF-κB super family of transcription factors. ER,PR and HER-2/neu were measured by immunohistochemistry methods. NF-κB/p65 is significantly associated with large tumor size (≥5 cm), high grade tumors, negative ER, negative PR, positive HER-2/neu and high NPI (≥5.4) scores. NF-κB/p65 expression implies aggressive biological behaviour of breast cancer & this study validates significant association of NF-κB /p65 overexpression with large tumor size, negative estrogen & progesterone receptor status and overexpression of c-erbB2 oncoprotein.

Entities:  

Keywords:  Breast cancer; Immunohistochemistry (IHC); NF-κB /p65 overexpression; Nottingham Prognostic Index (NPI); Nuclear factor-κB (NF-κB); Prognostic marker

Year:  2013        PMID: 24426730      PMCID: PMC3771050          DOI: 10.1007/s13193-013-0234-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  17 in total

1.  Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor.

Authors:  E Kalkhoven; S Wissink; P T van der Saag; B van der Burg
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

2.  Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.

Authors:  D K Biswas; A P Cruz; E Gansberger; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 3.  Pro-apoptotic role of NF-kappaB: implications for cancer therapy.

Authors:  Senthil K Radhakrishnan; Sitharthan Kamalakaran
Journal:  Biochim Biophys Acta       Date:  2006-03-03

4.  The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Authors:  D K Biswas; S C Dai; A Cruz; B Weiser; E Graner; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

5.  Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Authors:  Yamei Zhou; Serenella Eppenberger-Castori; Corina Marx; Christina Yau; Gary K Scott; Urs Eppenberger; Christopher C Benz
Journal:  Int J Biochem Cell Biol       Date:  2005-05       Impact factor: 5.085

Review 6.  Nuclear factor-kappaB activation: from bench to bedside.

Authors:  Gautam Sethi; Bokyung Sung; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2008-01

7.  The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer.

Authors:  Ming Feng Hou; Shwu Bin Lin; Shyng Shiou F Yuan; Shih Meng Tsai; Szu Hua Wu; Fu Ou-Yang; Jan Shih Hsieh; Kun Bow Tsai; Tsung Jen Huang; Li Yu Tsai
Journal:  Clin Chim Acta       Date:  2003-08       Impact factor: 3.786

8.  Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation.

Authors:  Debajit K Biswas; Katherine J Martin; Cliona McAlister; Antonio P Cruz; Edgard Graner; Sun-chun Dai; Arthur B Pardee
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

Review 9.  NF-κB, stem cells and breast cancer: the links get stronger.

Authors:  Kateryna Shostak; Alain Chariot
Journal:  Breast Cancer Res       Date:  2011-07-26       Impact factor: 6.466

10.  NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Authors:  S J Van Laere; I Van der Auwera; G G Van den Eynden; P van Dam; E A Van Marck; P B Vermeulen; L Y Dirix
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more
  9 in total

1.  Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.

Authors:  Debarshi Jana; Diptendra Kumar Sarkar; Suvro Ganguly; Shilpi Saha; Gaurisankar Sa; Asim Kumar Manna; Abhirup Banerjee; Syamsundar Mandal
Journal:  Indian J Surg Oncol       Date:  2014-02-12

2.  The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia.

Authors:  Christian Manginstar; Andi Asadul Islam; Daniel Sampepajung; William Hamdani; Agussalim Bukhari; Salman Ardy Syamsu; Nilam Smaradania; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2021-02-10

3.  The relationship between members of the canonical NF-κB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer.

Authors:  Lindsay Bennett; Elizabeth A Mallon; Paul G Horgan; Andrew Paul; Donald C McMillan; Joanne Edwards
Journal:  Oncotarget       Date:  2017-05-16

4.  Expression of Nrf2 and NF-κB transcription factors in breast cancer and breast fibroadenoma: Insights for a new therapeutic approach.

Authors:  Camila Maria Simplicio-Revoredo; Renato de Oliveira Pereira; Mariella de Almeida Melo; Pedro Vitor Lopes-Costa; Paulo de Tarso Moura-Borges; Emerson Brandão Sousa; Fidelis Manes Neto; Viriato Campelo; Ione Maria Ribeiro Soares-Lopes; Maria da Conceição Barros-Oliveira; Cleciton Braga Tavares; Alesse Ribeiro Dos Santos; Camila Guedes Borges de Araújo; Eid Gonçalves Coelho; Larysse Cardoso Campos-Verdes; Aldenora Oliveira do Nascimento-Holanda; Jackeline Lopes Viana; Maria Liduina Meneses Bezerra-Chaves; Rodrigo José de Vasconcelos-Valença; Lina Gomes Dos Santos; Lauro Rodolpho Soares-Lopes; André Luiz Pinho-Sobral; Luiz Henrique Gebrim; Benedito Borges da Silva
Journal:  Oncotarget       Date:  2020-05-05

5.  Short-Term Microgravity Influences Cell Adhesion in Human Breast Cancer Cells.

Authors:  Mohamed Zakaria Nassef; Sascha Kopp; Daniela Melnik; Thomas J Corydon; Jayashree Sahana; Marcus Krüger; Markus Wehland; Thomas J Bauer; Christian Liemersdorf; Ruth Hemmersbach; Manfred Infanger; Daniela Grimm
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

6.  Targeted Transdermal Delivery of Curcumin for Breast Cancer Prevention.

Authors:  Michele Atlan; Josh Neman
Journal:  Int J Environ Res Public Health       Date:  2019-12-06       Impact factor: 3.390

7.  Study of the Possible Alleviated Role of Atorvastatin on Irinotecan-Induced Lingual Mucosal Damage: Histological and Molecular Study.

Authors:  Eetmad A Arafat; S M Abo El-Khair; A Z Elsamanoudy; Dalia A Shabaan
Journal:  Oxid Med Cell Longev       Date:  2021-09-30       Impact factor: 6.543

8.  Identification of a novel 1,2 oxazine that can induce apoptosis by targeting NF-κB in hepatocellular carcinoma cells.

Authors:  Chaithanya Somu; Chakrabhavi Dhananjaya Mohan; Sachin Ambekar; Shobith Rangappa; C P Baburajeev; Alexey Sukhorukov; Srishti Mishra; Muthu K Shanmugam; Arunachalam Chinnathambi; Tahani Awad Alahmadi; Sulaiman Ali Alharbi; Kanchugarakoppal S Rangappa
Journal:  Biotechnol Rep (Amst)       Date:  2020-02-19

9.  Anthocyanidins Inhibit Growth and Chemosensitize Triple-Negative Breast Cancer via the NF-κB Signaling Pathway.

Authors:  Farrukh Aqil; Radha Munagala; Ashish K Agrawal; Jeyaprakash Jeyabalan; Neha Tyagi; Shesh N Rai; Ramesh C Gupta
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.